Glenn Macnichol, MD
Interventional Pain Medicine · Rocky Mount, NCNPI 1245297811
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 318 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Abbott at 35.9% of the total.
Across 318 payments — averaging $12.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$447
- Collegium Pharmaceutical, Inc.$389
- IBSA Pharma Inc.$333
- Scilex Pharmaceuticals Inc.$193
- Nevro Corp.$157
- plus $1K from 26 others
What the payments were for
- Food & beverage$4,08199%
- Entertainment$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 170 | $1,475 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $447 |
| Collegium Pharmaceutical, Inc. | 19 | $389 |
| IBSA Pharma Inc. | 17 | $333 |
| Scilex Pharmaceuticals Inc. | 12 | $193 |
| Nevro Corp. | 10 | $157 |
| Radius Health, Inc. | 6 | $134 |
| Pfizer | 8 | $133 |
| Globus Medical | 4 | $81 |
| Masimo Corporation | 4 | $71 |
| Arbor Pharmaceuticals, Inc. | 5 | $70 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Redhill Biopharma Inc. | 3 | $47 |
| Smith+Nephew | 3 | $43 |
| Vertex | 2 | $42 |
| Biodelivery Sciences International, Inc. | 3 | $41 |
| Virtus Pharmaceuticals LLC | 2 | $37 |
| Organogenesis Inc. | 1 | $36 |
| Amgen | 2 | $34 |
| AbbVie | 2 | $32 |
| Bioventus LLC | 2 | $30 |
| KCI USA, Inc. | 1 | $29 |
| Zimmer Biomet | 2 | $29 |
| MDD US Operations, LLC | 2 | $28 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $24 |
| Lilly USA, LLC | 2 | $22 |
| Integra Lifesciences Corporation | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Valinor Pharma, LLC | 1 | $19 |
| Avanos Medical | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Boston Scientific | 1 | $13 |
How this compares
$4,105 in reported general payments places this provider in the 55th percentile of 45 interventional pain medicine providers in North Carolina.
See all interventional pain medicine providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 37 | $91,228 |
| Xtampza ErOxycodone Myristate | 64 | $36,315 |
| LinzessLinaclotide | 11 | $11,657 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 427 | $11,062 |
| Buprenorphine | 41 | $9,199 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 266 | $9,010 |
| Gabapentin | 480 | $7,019 |
| Pregabalin | 199 | $5,070 |
| Nucynta ErTapentadol Hcl | 11 | $5,041 |
| Diclofenac Sodium | 60 | $2,737 |
| Celecoxib | 73 | $2,535 |
| Morphine Sulfate ErMorphine Sulfate | 137 | $2,480 |
| Lidocaine | 16 | $1,651 |
| Tramadol Hcl ErTramadol Hcl | 17 | $1,391 |
| Tramadol Hcl | 168 | $1,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $447 | $91,22837 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er | $389 | $41,35675 claims |
| AbbVieLinzess | $32 | $11,65711 claims |
| Virtus Pharmaceuticals LLCLactulose | $37 | $13013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 45 interventional pain medicine providers in North Carolina.
Other interventional pain medicine in Rocky Mount
- Timothy ChafinAhoskie$59K
- Robert WilsonSalisbury$37K
- John MansfieldAsheville$25K
- Erin ChaneyJacksonville$22K
- Kevin CostelloGreenville$22K
- Scott JohnstonJacksonville$20K
- Harsh GovilStatesville$19K
- Troy GingerichCharlotte$19K
- Brent HarkriderNew Bern$14K
- Carey-Walter ClossonCharlotte$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.